Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;57(9):4222-4228.
doi: 10.1128/AAC.01885-12. Epub 2013 Jun 24.

Targeting the "Rising DAMP" during a Francisella tularensis Infection

Riccardo V D'Elia  1 , Thomas R Laws  2 , Alun Carter  2 , Roman Lukaszewski  2 , Graeme C Clark  2
Affiliations

Targeting the "Rising DAMP" during a Francisella tularensis Infection

Riccardo V D'Elia et al. Antimicrob Agents Chemother. 2013 Sep.

Abstract

Antibiotic efficacy is greatly enhanced the earlier it is administered following infection with a bacterial pathogen. However, in a clinical setting antibiotic treatment usually commences following the onset of symptoms, which in some cases (e.g., biothreat agents) may be too late. In a BALB/c murine intranasal model of infection for Francisella tularensis SCHU S4 infection, we demonstrate during a time course experiment that proinflammatory cytokines and the damage-associated molecular pattern HMGB1 were not significantly elevated above naive levels in tissue or sera until 72 h postinfection. HMGB1 was identified as a potential therapeutic target that could extend the window of opportunity for the treatment of tularemia with antibiotics. Antibodies to HMGB1 were administered in conjunction with a delayed/suboptimal levofloxacin treatment of F. tularensis We found in the intranasal model of infection that treatment with anti-HMGB1 antibody, compared to an isotype IgY control antibody, conferred a significant survival benefit and decreased bacterial loads in the spleen and liver but not the lung (primary loci of infection) 4 days into infection. We also observed an increase in the production of gamma interferon in all tested organs. These data demonstrate that treatment with anti-HMGB1 antibody is beneficial in enhancing the effectiveness of current antibiotics in treating tularemia. Strategies of this type, involving antibiotics in combination with immunomodulatory drugs, are likely to be essential for the development of a postexposure therapeutic for intracellular pathogens.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Bacterial colonization in organs following intranasal infection with F. tularensis strain SCHU S4. Bacterial numbers were enumerated on supplemented BCGA plates for three organs: lung (A), liver (B), and spleen (C). Each data point represents a single mouse, and lines indicate the median. Data shown are for two independent experiments. The calculated doses for experiments 1 and 2 were 99 and 89 CFU, respectively: 7 mice (experiment 1) and 5 mice (experiment 2) were culled at days 1 to 4 p.i., and 4 mice (experiment 1) and 1 mouse (experiment 2) were culled at day 5 p.i. (remaining survivors). An additional 5 mice were used to establish a baseline/naive concentration (day 0).
Fig 2
Fig 2
Organ cytokine profile following intranasal infection with F. tularensis strain SCHU S4. Levels of IL-6, MCP-1, IFN-γ, TNF-α, IL-10, and IL-12p70 were measured via Cytometric Bead Array (CBA) plate counts. Cytokine concentrations are displayed as pg/g per organ (lung, liver, and spleen). Each data point represents a single mouse, and the lines indicate the medians. Data shown are for two independent experiments. The calculated doses for experiments 1 and 2 were 99 and 89 CFU, respectively. Seven mice (experiment 1) and 5 mice (experiment 2) were culled at days 1 to 4 p.i. Four mice (experiment 1) and 1 mouse (experiment 2) were culled at day 5 p.i. (remaining survivors). An additional 5 mice were used to establish a baseline/naive concentration (day 0).
Fig 3
Fig 3
Serum HMGB1 release in mice following intranasal infection with F. tularensis strain SCHU S4. Levels of serum HMGB1 (ng/ml) were assessed via ELISA. Each data point represents a single mouse, and the lines indicate the medians. Data shown are for two independent experiments. The calculated doses for experiments 1 and 2 were 99 and 89 CFU, respectively. Seven mice (experiment 1) and 5 mice (experiment 2) were culled at days 1 to 4 p.i.; 4 mice (experiment 1) and 1 mouse (experiment 2) were culled at day 5 p.i. (remaining survivors). An additional 13 mice were used to establish a baseline/naive concentration (day 0).
Fig 4
Fig 4
Survival of mice following anti-HMGB1 Ab treatment in combination with levofloxacin. Male BALB/c mice were challenged with 87 CFU (experiment 1), 77 (experiment 2), or 103 CFU (experiment 3) F. tularensis SCHU S4 via the intranasal route. Groups were treated with either 600 μg of anti-HMGB1 Ab or 600 μg of an isotype control (IgY) at 48 and 72 h p.i. Levofloxacin (40 mg/kg) was administered via the intraperitoneal route at 96 h p.i. and continued once daily for 7 days for both groups. Each data point represents the percentage of survivors in each group at the corresponding time point. In the first experiment, 7 animals received anti-HMGB1 Ab and 17 animals received isotype control IgY; in the second and third experiments, 10 animals received anti-HMGB1 Ab and 10 animals received isotype control IgY. Data were analyzed by stratified log rank test.
Fig 5
Fig 5
Bacterial colonization in anti-HMGB1- and IgY Ab-treated mice. Male BALB/c mice were challenged with 87 CFU (experiment 1), 77 CFU (experiment 2), and 103 CFU (experiment 3) F. tularensis SCHU S4 via the intranasal route. Mice were culled at 96 h p.i. and bacteria enumerated on supplemented BCGA for the lung, liver, and spleen. Groups were treated with either 600 μg of anti-HMGB1 Ab or 600 μg of an isotype control Ab (IgY) at 48 and 72 h p.i. Each data point represents a mouse, and the lines represent the medians. In the first experiment, 4 animals received anti-HMGB1 Ab and 7 animals received isotype control IgY Ab; in the second and third experiments, 5 animals received anti-HMGB1 Ab and 5 animals received isotype control IgY Ab. Data were analyzed by univariate linear models of the log10 transformed data.
Fig 6
Fig 6
Cytokine production in anti-HMGB1- and IgY Ab-treated mice. Male BALB/c mice were challenged with 87 CFU (experiment 1), 77 CFU (experiment 2), and 103 CFU (experiment 3) F. tularensis SCHU S4 via the intranasal route. Mice were culled at 96 h p.i. and IFN-γ and MCP-1 cytokines assayed for the lung, liver, and spleen. Groups were treated with either 600 μg of anti-HMGB1 Ab or 600 μg of an isotype control (IgY) Ab at 48 and 72 h p.i. Each data point represents a mouse, and the lines represent the medians. In the first experiment, 4 animals received anti-HMGB1 Ab and 7 animals received isotype control IgY Ab; in the second and third experiments, 5 animals received anti-HMGB1 Ab and 5 animals received isotype control IgY Ab. Data were analyzed by the univariate linear model of the log10 transformed data. Significance markers have been included to show differences associated with the different treatments. Levels of IL-6, IL-10, TNF-α, and IL-12p70 were also determined but are not shown.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. D'Elia R, Jenner DC, Laws TR, Stokes MGM, Jackson MC, Essex-Lopresti AE, Atkins HS. 2011. Inhibition of Francisella tularensis LVS infection of macrophages results in a reduced inflammatory response: evaluation of a therapeutic strategy for intracellular bacteria. FEMS Immunol. Med. Microbiol. 62:348–361 - PubMed
    1. Hall JD, Woolard MD, Gunn BM, Craven RR, Taft-Benz S, Frelinger JA, Kawula TH. 2008. Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112. Infect. Immun. 76:5843–5852 - PMC - PubMed
    1. Ellis J, Oyston PCF, Green M, Titball RW. 2002. Tularemia. Clin. Microbiol. Rev. 15:631–646 - PMC - PubMed
    1. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, Mcdade JE, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K. 2001. Tularemia as a biological weapon—medical and public health management. JAMA 285:2763–2773 - PubMed
    1. Kortepeter MG, Parker GW. 1999. Potential biological weapons threats. Emerg. Infect. Dis. 5:523–527 - PMC - PubMed

LinkOut - more resources